Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NGM

NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis

NGM Biopharmaceuticals logo

About NGM Biopharmaceuticals Stock (NASDAQ:NGM)

Advanced Chart

Key Stats

Today's Range
$1.54
$1.54
50-Day Range
$1.52
$1.63
52-Week Range
$0.60
$4.69
Volume
N/A
Average Volume
1.47 million shs
Market Capitalization
$128.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NGM Biopharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

NGM MarketRank™: 

NGM Biopharmaceuticals scored higher than 32% of companies evaluated by MarketBeat, and ranked 753rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for NGM Biopharmaceuticals.

  • Earnings Growth

    Earnings for NGM Biopharmaceuticals are expected to grow in the coming year, from ($0.93) to ($0.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NGM Biopharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NGM Biopharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NGM Biopharmaceuticals has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for NGM.
  • Dividend Yield

    NGM Biopharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    NGM Biopharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for NGM.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for NGM Biopharmaceuticals this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, NGM Biopharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    35.90% of the stock of NGM Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.74% of the stock of NGM Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NGM Biopharmaceuticals' insider trading history.
Receive NGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NGM Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

NGM Stock Analysis - Frequently Asked Questions

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.03. The company earned $18.58 million during the quarter, compared to the consensus estimate of $18.90 million. NGM Biopharmaceuticals had a negative net margin of 3,223.34% and a negative trailing twelve-month return on equity of 77.85%.

NGM Biopharmaceuticals (NGM) raised $100 million in an IPO on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that NGM Biopharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and PayPal (PYPL).

Company Calendar

Last Earnings
11/04/2021
Today
7/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:NGM
CIK
1426332
Fax
N/A
Employees
138
Year Founded
1998

Profitability

EPS (Trailing Twelve Months)
($1.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$142.38 million
Net Margins
-3,223.34%
Pretax Margin
-3,223.34%
Return on Equity
-77.85%
Return on Assets
-67.76%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.79
Quick Ratio
7.79

Sales & Book Value

Annual Sales
$4.42 million
Price / Sales
29.10
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.80 per share
Price / Book
0.86

Miscellaneous

Outstanding Shares
83,462,000
Free Float
53,499,000
Market Cap
$128.53 million
Optionable
Optionable
Beta
1.27

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:NGM) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners